vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes

vTv Therapeutics ( (VTVT) ) has issued an announcement.

On May 16, 2025, vTv Therapeutics, Inc. released a slide presentation highlighting the potential of Cadisegliatin, a liver-selective glucokinase activator, as a groundbreaking oral adjunct therapy for type 1 diabetes. The presentation emphasized the drug’s ability to improve glucose homeostasis and glycogen storage, addressing the challenges of hypoglycemia and poor glycemic control faced by patients. With the FDA Breakthrough Designation and promising Phase 3 data expected in the second half of 2026, Cadisegliatin could significantly impact the treatment landscape for type 1 diabetes, offering hope to millions of patients struggling to manage their condition.

The most recent analyst rating on (VTVT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.

vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.

To see Spark’s full report on VTVT stock, click here.

More about vTv Therapeutics

vTv Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for type 1 diabetes. The company is working on Cadisegliatin, a potential first oral adjunct therapy for type 1 diabetes, targeting a market with significant unmet needs.

Average Trading Volume: 22,521

Technical Sentiment Signal: Buy

Current Market Cap: $68.08M

See more data about VTVT stock on TipRanks’ Stock Analysis page.